NASDAQ · DXR
Healthcare · Medical - Instruments & Supplies
$8.70
Up+$0.10 (+1.15%)
Updated Nov 4, 2026, 8:52 PM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DXR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
DXR closed at $8.70 after 21 trading sessions, down 15.53% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $8.89 | $8.95 | $8.50 | $8.70 | 36.11K |
| Nov 2, 2026 | $9.19 | $9.19 | $8.90 | $9.00 | 3.7K |
| Oct 30, 2026 | $8.86 | $9.20 | $8.40 | $9.20 | 28.01K |
| Oct 29, 2026 | $8.84 | $8.98 | $8.84 | $8.92 | 3.67K |
| Oct 28, 2026 | $8.76 | $9.0499 | $8.76 | $8.97 | 16.22K |
| Oct 27, 2026 | $8.87 | $9.20 | $8.77 | $8.89 | 8.16K |
| Oct 26, 2026 | $9.00 | $9.23 | $9.00 | $9.21 | 9.61K |
| Oct 23, 2026 | $9.68 | $9.68 | $9.24 | $9.25 | 21.05K |
| Oct 22, 2026 | $9.86 | $9.86 | $9.34 | $9.40 | 15.28K |
| Oct 21, 2026 | $9.61 | $9.77 | $9.60 | $9.77 | 11.26K |
| Oct 20, 2026 | $10.04 | $10.04 | $9.70 | $9.75 | 2.84K |
| Oct 19, 2026 | $10.12 | $10.12 | $9.68 | $9.84 | 7.88K |
| Oct 16, 2026 | $10.20 | $10.28 | $10.05 | $10.05 | 4.47K |
| Oct 15, 2026 | $10.36 | $10.36 | $10.08 | $10.20 | 24.43K |
| Oct 14, 2026 | $10.50 | $10.50 | $9.95 | $10.09 | 15.5K |
| Oct 13, 2026 | $10.36 | $10.58 | $10.07 | $10.35 | 19.57K |
| Oct 12, 2026 | $10.49 | $10.49 | $10.21 | $10.304 | 4.77K |
| Oct 9, 2026 | $10.51 | $10.71 | $10.41 | $10.41 | 7.46K |
| Oct 8, 2026 | $10.67 | $10.67 | $10.36 | $10.46 | 3.45K |
| Oct 7, 2026 | $10.41 | $10.78 | $10.02 | $10.51 | 7.38K |
| Oct 6, 2026 | $10.43 | $10.43 | $10.3001 | $10.3001 | 2.86K |
The latest Smart Investors Daily articles mentioning DXR.
Company
Market Activity
Research & News
DXR research
Company profile and research snapshot.
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 17, 2025 | Ascendiant Capital | Buy | — |
| Sep 9, 2024 | Ascendiant Capital | Buy | — |
| Jul 29, 2019 | Maxim Group | Buy | — |
| May 16, 2019 | Ascendiant | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Mar 10, 2026
Daxor Corporation (DXR) IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 March 10, 2026 2:00 PM EDTCompany ParticipantsMichael Feldschuh -...
Benzinga · Feb 24, 2026
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading
Benzinga · Feb 10, 2026
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940
Benzinga · Feb 10, 2026
"The strategic decision to transition back to Exchange Act reporting is a financial validation of our focused growth strategy," said Robert Michel, Daxor's Chief Financial Officer. "Daxor has achieved the scale necessary
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DXR.
